Scarica l'app Stockscreener
24.16
1.64%
0.39
Pre-mercato:
24.02
-0.14
-0.58%
Precedente Chiudi:
$23.77
Aprire:
$23.65
Volume 24 ore:
1.20M
Relative Volume:
0.64
Capitalizzazione di mercato:
$2.64B
Reddito:
-
Utile/perdita netta:
$-237.54M
Rapporto P/E:
-9.6513
EPS:
-2.5033
Flusso di cassa netto:
$-145.05M
1 W Prestazione:
+5.27%
1M Prestazione:
+15.10%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$23.47
$24.28
Intervallo di 1 settimana:
$22.73
$25.23
Portata 52W:
$14.62
$26.25
Definium Therapeutics Inc Stock (DFTX) Company Profile
Nome
Definium Therapeutics Inc
Settore
Industria
Telefono
212-220-6633
Indirizzo
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
24.16 | 2.59B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | Stifel | Buy |
| 2026-04-10 | Iniziato | Piper Sandler | Overweight |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-08-04 | Ripresa | Oppenheimer | Outperform |
| 2025-01-28 | Iniziato | Evercore ISI | Outperform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-07-24 | Iniziato | ROTH MKM | Buy |
| 2024-05-29 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | Canaccord Genuity | Buy |
| 2022-12-09 | Ripresa | ROTH Capital | Buy |
| 2022-11-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-26 | Iniziato | Oppenheimer | Outperform |
| 2022-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Iniziato | ROTH Capital | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Definium Therapeutics Inc Borsa (DFTX) Ultime notizie
Definium Therapeutics Announces New Employee Inducement GrantsJune 15, 2026 - BioSpace
Definium Therapeutics (DFTX) director receives RSU and stock option grants - Stock Titan
Definium Therapeutics (DFTX) director awarded RSUs and stock options in new grant - Stock Titan
Definium Therapeutics (DFTX) awards RSUs and stock options to director Krebs - Stock Titan
Definium Therapeutics (DFTX) director granted RSUs and stock options in equity award - Stock Titan
Definium Therapeutics (DFTX) director granted RSUs and 19,188 stock options - Stock Titan
Six new Definium hires receive options on 155,480 shares - Stock Titan
Definium Therapeutics, Inc. Announces 2026 Annual Meeting Results and Key SEC Filings - Minichart
Definium Therapeutics (NASDAQ: DFTX) OKs 5M-share equity plan boost - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
How Approaching DT120 Phase III Readouts At Definium Therapeutics (DFTX) Have Changed Its Investment Story - Sahm
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
DFTX: Director elections, auditor appointment, and equity plan amendment approved; clinical trial results expected late Q2 - TradingView
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation As Shares Show Strong Recent Momentum - Yahoo Finance
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Definium earnings on deck as pivotal psychedelic trial data looms By Investing.com - Investing.com Nigeria
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $44 - Moomoo
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Definium Therapeutics eyes key DT-120 depression data, advances anxiety program - MSN
Definium Therapeutics Inc (DFTX) Stock Price Quote Today & Current Price Chart | Capital.com UAE - Capital.com
Definium Therapeutics nears key depression drug trial results - MSN
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program - Yahoo Finance
Jefferies Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class Potential - Seeking Alpha
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
Definium Begins Second Phase 3 DT120 Trial As Valuation Gap Widens - Yahoo Finance
Definium Therapeutics Nears Pivotal Earnings Call Tests - The Globe and Mail
Definium Therapeutics convenes lawmakers and researchers to advance psychedelic medicine discourse - Traders Union
Definium Therapeutics Advances DT120 ODT for GAD and MDD With Promising Phase 3 Data and Billion-Dollar Market Potential - Minichart
Definium Highlights Late-Stage Psychedelic-Inspired Psychiatric Pipeline - TipRanks
Definium Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash - TradingView
Definium Therapeutics (NASDAQ: DFTX) maps DT120 Phase 3 path and 2026 data - Stock Titan
Definium Therapeutics presents pre-clinical safety data on new psychedelic treatment at APA meeting - Traders Union
Definium Therapeutics (DFTX) Institutional Ownership 2026 - MarketBeat
Trump's psychedelic drug order boosts investor interest with promise of faster reviews - Reuters
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Definium Therapeutics Inc Azioni (DFTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Definium Therapeutics Inc Azioni (DFTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer |
Mar 25 '26 |
Sale |
18.47 |
10,702 |
197,666 |
271,079 |
| Barrow Robert | Chief Executive Officer |
Mar 25 '26 |
Sale |
18.47 |
24,431 |
451,241 |
752,454 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):